Copper Cu 64 Zadavotide Guraxetan clinical trials
How each study uses Copper Cu 64 Zadavotide Guraxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Copper Cu 64 PSMA I&T
- 2
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Curium US LLC (3)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses Copper Cu 64 Zadavotide Guraxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerCompletedPhase 3Curium US LLCNCT06235151Written as Copper Cu 64 PSMA I&THow we know
- Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate CancerCompletedPhase 3Curium US LLCNCT06235099Written as Copper Cu 64 PSMA I&THow we know
- Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate CancerCompletedPhase 2Curium US LLCNCT05653856Written as 64Cu-PSMA I&THow we know
Codes
What other systems call Copper Cu 64 Zadavotide Guraxetan · ClinicalTrials.gg INT016968
- UNII (FDA) JN9XS4J584COPPER CU-64 ZADAVOTIDE GURAXETANOne source FDA
- NCI Thesaurus C192225Copper Cu 64 Zadavotide GuraxetanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JN9XS4J584 | COPPER CU-64 ZADAVOTIDE GURAXETAN | One source FDA |
| NCI Thesaurus | C192225 | Copper Cu 64 Zadavotide Guraxetan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.